ArticleNature communications2025
Injectable extracellular vesicle hydrogels with tunable viscoelasticity for depot vaccine.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Spatiotemporal delivery of exosomes and alendronate orchestrates osteoblastic and osteoclastic activity for osteoporotic bone regeneration.Bioactive materials · 2026Article
- Dental Pulp Stem Cell-Derived Secretome-Induced Reprogramming of Tongue Tumor Microenvironment.European journal of dentistry · 2026Article
- Encapsulation and Controlled Release of Human Spinal Cord Organoid-Derived Extracellular Vesicles for Tissue Patterning in Viscoelastic Hyaluronic Acid Hydrogels.Advanced healthcare materials · 2026Article
- Plant-derived extracellular vesicles as emerging cardioprotective agents for cardiovascular diseases.Journal of nanobiotechnology · 2026Review
- Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.Drug delivery and translational research · 2026Article
- Injectable and viscoelastic click alginate hydrogels for spatio-temporal T cell administration in vivo.Materials today. Bio · 2026Article
- Metabolic Tagging of Tumour Extracellular Vesicles for Targeted Modulation of Dendritic Cells.Journal of extracellular vesicles · 2026Article
- Apoptotic extracellular vesicles act as master regulators of the bone healing niche.Journal of nanobiotechnology · 2026Review
- Review
- Review
- Review
- A powerful bioorthogonal toolbox boosting the development of immune theranostics.Chemical science · 2025Review
- Mechanical Force Storage and Reprogramming Hydrogel for Scarless Repair of Sports Joint Wounds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy.Gels (Basel, Switzerland) · 2025Review
- Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms.Small science · 2025Review
- Advances of extracellular vesicles isolation and detection frontier technology: from heterogeneity analysis to clinical application.Journal of nanobiotechnology · 2025Review
- Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.Frontiers in bioengineering and biotechnology · 2025Review
- Modeling the pre-metastatic niche of gastric cancer peritoneal metastasis under spatiotemporal resolution and investigating EVs-mediated immune suppression.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Extracellular vesicles (EVs) have been actively explored for therapeutic applications in the context of cancer and other diseases. However, the poor tissue retention of EVs has limited the development of EV-based therapies. Here we report a facile approach to fabricating injectable EV hydrogels with tunable viscoelasticity and gelation temperature, by metabolically tagging EVs with azido groups and further crosslinking them with dibenzocyclooctyne-bearing polyethylene glycol via efficient click chemistry. One such EV gel has a gelation temperature of 39.4 °C, enabling in situ gelation of solution-form EVs upon injection into the body. The in situ formed gels are stable for over 4 weeks and can attract immune cells including dendritic cells over time in vivo. We further show that tumor EV hydrogels, upon subcutaneous injection, can serve as a long-term depot for EV-encased tumor antigens, providing an extended time for the modulation of dendritic cells and subsequent priming of tumor-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.